Astellas Pharma Inc. Newsletter
-
The Escalator: Astellas Pharma, Moderna, Minds + Assembly and more
06 Feb 2025 13:07 GMT
… and chief data officer.
Astellas Pharma announced chief medical officer … on April 1, 2025.
Astellas’ chief commercial officer Claus … general counsel.
Tonix Pharmaceuticals promoted Siobhan Fogarty to … end of last year.
Astellas’ Chief Scientific Officer …
-
Fierce Pharma Asia—China troubles at Merck, AZ; Astellas' C-suite shuffle and Izervay stumbles
07 Feb 2025 16:03 GMT
… slowdown for eye drug Izervay after regulatory stumbles
Meanwhile, Astellas’ key launch … of the geographic atrophy drug Izervay hit … . The policy could also pressure pharmaceutical supply chains, raising medical costs …
-
Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy
06 Feb 2025 04:16 GMT
Astellas Pharma Inc., a global life sciences … the submission of a New Drug Application (NDA) to Japan’ … of biopharma and ophthalmology development, Astellas, said: “Today’s submission … pegol (ACP) is an investigational drug for treatment of geographic atrophy …
-
Antifungal Drugs Market Growth Outlook : Projected to Hit $ 25.0 Billion by 2030 at 3.9% CAGR
06 Feb 2025 07:52 GMT
… 2370
Market Segmentation:-
By Drug Class:
Azoles
Polyenes
Allylamines … ., Inc.
Johnson & Johnson
Astellas Pharma Inc.
GlaxoSmithKline plc
AbbVie Inc … activities to address drug-resistant fungal infections. Pharmaceutical companies are …
-
Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
06 Feb 2025 02:12 GMT
… 12 months on the drug. For Astellas' launch, the … recent financial report, Astellas called Izervay the leading … efficacy over Izervay.
Astellas executives pushed back against … Europe, neither drug has made it onto the market. Astellas clawed back …
-
Astellas Submits NDA for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
05 Feb 2025 16:20 GMT
Astellas Pharma Inc. announced the submission of a New Drug Application (NDA) to Japan … of BioPharma and Ophthalmology Development, Astellas
"Today's submission … , get special offers
from American Pharmaceutical Review – all delivered right to …
-
Astellas seeks conditional approval for GA treatment in Japan
05 Feb 2025 15:44 GMT
Astellas Pharma has submitted a new drug application (NDA) to Japan’s … consistent restriction in lesion growth.
Astellas bioPharma and ophthalmology development head … of GA.
In December 2024, Astellas Pharma and Sangamo Therapeutics signed an …
-
Astellas Submits New Drug Application For Conditional Approval Of Avacincaptad Pegol For Geographic Atrophy In Japan
05 Feb 2025 10:41 GMT
… 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President … ;Astellas") today announced the submission of a New Drug … ACP) is an investigational drug for treatment of geographic … ;14:15–28.
SOURCE Astellas Pharma Inc.
WANT YOUR COMPANY…
-
Astellas Makes Changes to Management Structure
05 Feb 2025 01:04 GMT
Astellas Pharma Inc. announced a number … 1, 2025.
To promote drug discovery activities swiftly and efficiently … with patient-centric approach, Astellas will change its management … next-generation groundbreaking therapies from Astellas. Effective April 1, 2025 …
-
Astellas shakes up management despite impressive nine-month earnings
04 Feb 2025 23:08 GMT
About
© 1995-2025